Sasanlimab plus bacillus Calmette-Guérin in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Exploratory biomarker analysis of the phase 3 CREST trial. Germline DNA repair gene (gDRG) ...
New trials target hard-to-treat cancers with more personalized, less toxic therapies, including pediatric brain tumors, colorectal, ovarian, bladder cancers, and leukemia. FDA cleared Reyobiq for ...
Whole genome–based ultrasensitive circulating tumor DNA clearance as a biomarker of exceptional outcomes with enfortumab vedotin and pembrolizumab in urothelial carcinoma: Preliminary real-world ...
A team from the Spanish National Cancer Research Centre (CNIO) has discovered a novel way in which tumor cells alter the brain to establish themselves and spread cancer. They also demonstrate that a ...
The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...
N1 Single lymph node metastasis, 2 cm or less in greatest dimension N1 Single regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac or presacral lymph node) N2 ...
The CATNON trial showed adjuvant Temodar benefits grade 3 glioma patients, with no added benefit from concurrent chemotherapy, reducing potential toxicity. HER3-DXd, an antibody-drug conjugate, ...
Active surveillance is noninferior to BCG induction therapy for invasive relapse-free survival in patients with high-grade T1 bladder cancer with no residual tumor on second TURBT. For patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results